Comment sécuriser les traitements par les biomédicaments ? Bull, Acad. Natle Méd, vol.195, issue.3, pp.679-698, 2011. ,
Traitement du lupus érythémateux disséminé par anticorps monoclonaux : un exemple d ,
Les anticorps monoclonaux, de la production à l'utilisation en oncologie, Thèse d'exercice en Pharmacie. Faculté de Pharmacie de Nancy, 2009. ,
De la s??roth??rapie aux anticorps recombinants ????nus????, m??decine/sciences, vol.25, issue.12, pp.999-100, 2009. ,
DOI : 10.1051/medsci/20092512999
Les anticorps : mieux les conna??tre pour mieux s???en servir, m??decine/sciences, vol.25, issue.12, pp.1011-1020, 2009. ,
DOI : 10.1051/medsci/200925121011
Les immunoconjugu??s, anticorps ????arm??s???? pour combattre le cancer, m??decine/sciences, vol.25, issue.12, pp.1046-52, 2009. ,
DOI : 10.1051/medsci/200925121046
Prot??ine de fusion ou anticorps monoclonal, m??decine/sciences, vol.25, issue.12, pp.1033-1041, 2009. ,
DOI : 10.1051/medsci/200925121033
Ingénierie de fragments d'anticorps pour l'imagerie in vivo de cancers de la sphère génitale, Thèse de doctorat, 2012. ,
Anticorps humanis??s en th??rapeutique, Médecine/Sciences, pp.1054-1062, 2005. ,
DOI : 10.1051/medsci/200521121054
THE B7???CD28 SUPERFAMILY, Nature Reviews Immunology, vol.12, issue.2, pp.116-126, 2002. ,
DOI : 10.1038/35069118
THE B7???CD28 SUPERFAMILY, Nature Reviews Immunology, vol.12, issue.2, pp.116-126, 2002. ,
DOI : 10.1038/35069118
Les biothérapies anti-lymphocyte B : une histoire d'anticorps ,
Club Rhumatismes et inflammations) Centre de, Recherche des Cordeliers (CRC) INSERM UMRS, vol.872 ,
Monoclonal antibodies in cancer therapy, Cancer immunity, vol.12, issue.1, p.14, 2012. ,
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus, J Clin Invest, 2009. ,
C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma, Curr Opin Mol Ther, vol.12, issue.6, pp.770-779, 2010. ,
Sous la direction d, 1996. ,
Omalizumab (Xolair®) dans le traitement de l'asthme allergique persistant sévère, Rev Med Liège, vol.64, pp.5-6, 2009. ,
Anticorps monoclonaux ?? usage th??rapeutique : sp??cificit??s du d??veloppement clinique, ??valuation par les agences, suivi de la tol??rance ?? long terme, Th??rapie, vol.67, issue.4, pp.319-327, 2012. ,
DOI : 10.2515/therapie/2012043
Production des anticorps monoclonaux, Rev Med Liège, vol.64, issue.2, pp.5-6, 2009. ,
Immunological Methods: v.3. Edition Academic Press Novembre, 1985. ,
Bases immunologiques a la compréhension du concept d'anticorps monoclonal, Rev Med Liège, vol.64, pp.5-6, 2009. ,
Nomenclature internationale des différents types d'anticorps monoclonaux, Rev Med Liège, vol.64, pp.5-6, 2009. ,
Nouvelles avancées dans l'utilisation des anticorps monoclonaux en thérapeutique, Rev Med Liège, vol.64, pp.5-6, 2009. ,
Protéine de fusion ou anticorps monoclonal quel biomédicament choisir dans une maladie inflammatoire ? Médecine, Sciences, vol.25, pp.1033-1041, 2009. ,
DOI : 10.1051/medsci/200925121033
Isotype selection in antibody engineering, Nature Biotechnolog, vol.25, 2007. ,
Human IgG Subclasses: Useful diagnostic markers for immunocompetence ,
Molecular engineering and design of therapeutic antibodies, Current Opinion in Immunology, vol.20, pp.460-470, 2008. ,
Terminal sugars of Fc glycans influence antibody effector functions of IgGs, Current Opinion in Immunology, vol.20, pp.471-478, 2008. ,
Current and future issues in the manufacturing and development of monoclonal antibodies, Advanced Drug Delivery Reviews, vol.58, issue.5-6, pp.707-722, 2006. ,
DOI : 10.1016/j.addr.2006.05.002
Monoclonal antibody manufacturing in transgenic plants -myths and realities, Current Opinion in Biotechnology, vol.13, pp.630-635, 2002. ,
Process economics of industrial monoclonal antibody manufacture, Journal of Chromatography B, vol.848, issue.1, pp.8-18, 2007. ,
DOI : 10.1016/j.jchromb.2006.07.037
Microbials for the production of monoclonal antibodies and antibody fragments, Trends in Biotechnology, vol.32, issue.1, pp.1-7, 2013. ,
DOI : 10.1016/j.tibtech.2013.10.002
Présentation à la surface de phages filamenteux : les multiples applications du phage display. Last updated: 10, 2013. ,
Production of recombinant proteins by filamentous fungi, Biotechnology Advances, vol.30, pp.1119-1139, 2012. ,
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer, Pharmacological Research, vol.65, issue.1, pp.9-22, 2012. ,
DOI : 10.1016/j.phrs.2011.09.002
Les anticorps monoclonaux dans le traitement des maladies rhumatismales auto-immunes, Curriculum Forum Med Suisse, vol.8, issue.10, pp.182-186, 2008. ,
Ingénierie des anticorps monoclonaux. BIOFUTUR 288 ? MAI, 2008. ,
Etanercept in the treatment of rheumatoid arthritis, Therapeutics and Clinical Risk Management, vol.3, issue.1, pp.99-105 ,
DOI : 10.2147/tcrm.2007.3.1.99
N- and O-Glycosylation Analysis of Etanercept Using Liquid Chromatography and Quadrupole Time-of-Flight Mass Spectrometry Equipped with Electron-Transfer Dissociation Functionality, Analytical Chemistry, vol.86, issue.1, pp.576-584, 2014. ,
DOI : 10.1021/ac402726h
Analytical characterization of biosimilar antibodies and Fc-fusion proteins, TrAC Trends in Analytical Chemistry, vol.48, pp.81-95, 2013. ,
DOI : 10.1016/j.trac.2013.02.014
TNF Inhibitors: clinical utility in autoimmune diseases, Transl Res, 2014. ,
Anticorps monoclonaux th??rapeutiques en canc??rologie, Pathologie Biologie, vol.60, issue.4, pp.223-228, 2012. ,
DOI : 10.1016/j.patbio.2012.05.008
Safety and Effectiveness of Bevacizumab Treatment for Metastatic Colorectal Cancer: Final Results from the Avastin?? Registry ??? Investigation of Effectiveness and Safety (ARIES) Observational Cohort Study, Clinical Oncology, vol.26, issue.6, pp.323-332, 2014. ,
DOI : 10.1016/j.clon.2014.03.001
Régis Peffault de Latour. Anticorps monoclonal anti-C5 (éculizumab) dan l'hémoglobinurie paroxystique nocturne ,
Eculizumab for paroxysmal nocturnal haemoglobinuria, The Lancet, vol.373, issue.9665, pp.759-67, 2009. ,
DOI : 10.1016/S0140-6736(09)60001-5
The role of CTLA-4 in the regulation of T cell immune responses, Immunology and Cell Biology, vol.77, pp.1-10, 1999. ,
Structure???function relationships of the variable domains of monoclonal antibodies approved for cancer treatment, Critical Reviews in Oncology/Hematology, vol.64, issue.3, pp.210-225, 2007. ,
DOI : 10.1016/j.critrevonc.2007.04.011
URL : https://hal.archives-ouvertes.fr/hal-00193362
Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis, Cancer Treatment Reviews, vol.40, issue.10, 2014. ,
DOI : 10.1016/j.ctrv.2014.09.002
Voie de l???EGFR et m??canisme d???action des inhibiteurs de tyrosine kinase, Revue de Pneumologie Clinique, vol.63, issue.1, pp.2-5, 2007. ,
DOI : 10.1016/S0761-8417(07)90097-8
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy, Clinical & Experimental Immunology, vol.24, issue.2, pp.1-9 ,
DOI : 10.1111/j.1365-2249.2009.03992.x
Le rôle des anticorps monoclonaux dans la transplantation d'organes, Forum Med Suisse, vol.8, issue.11, pp.204-209, 2008. ,
Daclizumab (Zenapax??) inhibits early interleukin-2 receptor signal transduction events, Transplant Immunology, vol.8, issue.3 ,
DOI : 10.1016/S0966-3274(00)00021-6
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1846, issue.2 ,
DOI : 10.1016/j.bbcan.2014.07.007
Les anticorps monoclonaux dans le traitement de l'ostéoporose: bientôt déjà dans la pratique quotidienne, Forum Med Suisse, vol.8, pp.12-13229, 2008. ,
Rituximab: Mechanism of Action, Seminars in Hematology, vol.47, issue.2, pp.115-123, 2010. ,
DOI : 10.1053/j.seminhematol.2010.01.011
Immune mechanisms of new therapeutic strategies in multiple sclerosis???A focus on alemtuzumab, Clinical Immunology, vol.142, issue.1, pp.25-30, 2012. ,
DOI : 10.1016/j.clim.2011.04.006
Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. The Lancet Oncology, pp.517-526, 2014. ,
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM??anti-CD3) as a targeted cancer immunotherapy, Cancer Treatment Reviews, vol.36, issue.6, pp.458-467, 2010. ,
DOI : 10.1016/j.ctrv.2010.03.001
Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients, Journal of Neuroimmunology, vol.235, pp.70-76, 2011. ,
Escape from neutralization by there spiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein, Virology, vol.454, pp.455139-144, 2014. ,
Preventing RSV bronchiolitis in vulnerable infants: The role of palivizumab, Paediatric Respiratory Reviews, vol.10, issue.3, pp.143-147, 2009. ,
DOI : 10.1016/j.prrv.2009.06.002
Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV, Journal of Infection and Chemotherapy, vol.8, issue.3, pp.201-206, 2002. ,
DOI : 10.1007/s10156-002-0178-6
Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability, Toxicology and Applied Pharmacology, vol.273, issue.2, pp.298-313, 2013. ,
DOI : 10.1016/j.taap.2013.09.003
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2_ Breast Cancer, Clinical Breast Cancer, vol.11, issue.5, pp.275-82 ,
Image-Guided Radiotherapy for Prostate Cancer: A Prospective Trial of Concomitant Boost Using Indium-111???Capromab Pendetide (ProstaScint) Imaging, International Journal of Radiation Oncology*Biology*Physics, vol.81, issue.4, pp.423-429, 2011. ,
DOI : 10.1016/j.ijrobp.2011.01.048
Update on Fused Capromab Pendetide Imaging of Prostate Cancer, Clinical Prostate Cancer, vol.3, issue.4, pp.230-238, 2005. ,
Technology Insight: monoclonal antibody imaging of prostate cancer, Nature Clinical Practice Urology, vol.3, pp.216-225, 2006. ,
M??canismes de l???action des anticorps monoclonaux anti-CD20 et surveillance biologique de leurs effets, Revue du Rhumatisme, vol.76, issue.9, pp.826-832, 2009. ,
DOI : 10.1016/j.rhum.2009.03.009
Quel intérêt du dosage pour la pratique des biomédicaments et des anticorps induits ? réalités en rhumatologie, 2012. ,
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treatment Reviews, vol.36, issue.3, pp.56-61, 2010. ,
DOI : 10.1016/S0305-7372(10)70021-9
Therapeutic antibodies: Market considerations, disease targets and bioprocessing, International Journal of Pharmaceutics, vol.440, issue.1, pp.83-98, 2013. ,
DOI : 10.1016/j.ijpharm.2011.12.039
Development trends for human monoclonal antibody therapeutics, Nature Reviews Drug Discovery, vol.25, issue.10, pp.767-774, 2010. ,
DOI : 10.1038/nrd3229
Mechanistic model for the involvement of the neonatal Fc receptor in IgG disposition, Clinical Pharmacology Modelling and Simulation ,
Isotype selection in antibody engineering, Nature Biotechnology, vol.25, issue.12, 2007. ,
Antibody???drug conjugates???A new wave of cancer drugs, Bioorganic & Medicinal Chemistry Letters, vol.24, issue.23, pp.5357-5363, 2014. ,
DOI : 10.1016/j.bmcl.2014.10.021
Utilisation des anti-VEGF dans le traitement local de la DMLA et autres rétinopathies. 13 février 2014 Séminaire Conseil d'Administration ANSM. www.ansm.fr -[87] https, 2014. ,